Full Breakdown
Former Senator Ben Sasse Uses Extended Cancer Survival to Call for AI-Focused Deliberation and Expanded Access to Experimental Treatments
4/27/2026, 10:23:58 PM
Extending Life with an Experimental Cancer Therapy
Former U.S. senator Ben Sasse, diagnosed with stage-4 pancreatic cancer in December 2025, reports a 76 percent reduction in tumor volume after four months on a clinical-trial drug, daraxonrasib, developed by Revolution Medicines. He attributes his extended survival to “providence, prayer and a miracle drug.” The therapy targets a KRAS gene mutation that drives uncontrolled cell growth.
Background: Diagnosis, Treatment, and Personal Perspective
Sasse’s prognosis originally gave him three to four months. He now describes “extended time” while battling metastases in the lungs, liver, vascular system, and lymphatic tissue. The former Nebraska senator, who left the Senate in 2023 to become president of the University of Florida, says the diagnosis has sharpened his focus on national issues, particularly the impact of artificial intelligence (AI) and the need for deeper congressional deliberation.
Data on daraxonrasib’s Clinical Trial
Revolution Medicines reported that trial participants receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for comparable patients receiving standard chemotherapy. Sasse’s own imaging shows a 76 percent tumor-volume decline and markedly reduced pain, allowing him to function with less morphine. The drug remains under FDA review, with an expedited review timeline of one to two months cited by the agency.
Broader Concerns: AI, the Digital Revolution, and Congressional Deliberation
Sasse argues that Congress “is not wrestling with big or important questions” such as the long-term economic and security implications of AI. He warns that the digital revolution will “routinize” much economic activity, creating “ubiquitous abundance” while displacing jobs, and that younger workers can no longer assume lifelong employment. He calls for a shift from “sound-bite” politics to “deliberative, long-form discourse” at the federal level.
Official Statements from Sasse and Congressional Colleagues
Sasse repeatedly urged lawmakers to expand “deliberative” practices, suggesting the Senate should be “less like Instagram” and “more plodding, steady, boring, and trustworthy.” Senate Majority Leader John Thune described Sasse as “a fearless, passionate example that many of us can learn from and follow.” Democratic Senator Mark Warner noted that Sasse “never really thought about things as conservative, liberal; he thought about issues as future, past.”
Criticism of “Right-to-Try” Legislation
The 2018 “right-to-try” law, which Sasse co-sponsored, has faced criticism for potentially weakening patient protections. Critics argue that existing programs already facilitate access to investigational drugs for terminal patients, and that the law’s amendment in 2023 made it stricter than originally intended.
On-the-Ground Perspective: Patient Experience
Cancer survivor Mike Hugo, who accessed an experimental device under the “right-to-try” framework, said the treatment enabled him to attend “two daddy-daughter dances that no one said I would ever make.”
Conflicting Reports & Gaps
While trial data indicate a median survival of 13.2 months, Sasse’s personal timeline remains uncertain; he estimates “maybe a year” of additional life. The FDA’s final safety determination for daraxonrasib has not yet been published, leaving the drug’s broader availability unresolved.
Verbatim Quotes
- “providence, prayer and a miracle drug.” — Ben Sasse, former U.S. Senator
- “The lie I want to tell myself is that I'm the center of everything.” — Ben Sasse
- “The Congress is not wrestling with big or important questions right now.” — Ben Sasse
- “We've never lived in a world where 22-year-olds couldn't assume that the work they did they would be able to do until death or retirement. And we're never going to have that world again.” — Ben Sasse
- “The drug binds to the activating pocket of (the gene mutation) and shuts it down,” — Dr. Christopher Lieu, oncologist, University of Colorado Anschutz
- “two daddy-daughter dances that no one said I would ever make,” — Mike Hugo, cancer survivor
What’s Next
The FDA is expected to complete its expedited review of daraxonrasib within the next two months. Sasse plans to continue advocating for AI-focused policy discussions and for reforms to the “right-to-try” framework that would further decentralize treatment decisions to patients and their physicians.
